AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8004297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2129838 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg at night
Number of subjects: 282
Study 2129838 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg at night
Number of subjects: 282
Study 2129838 — intervention group
Group type: COMPARATOR
Intervention: 400 mg twice daily
Number of subjects: 282
Study 874649 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 50
Study 874649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31331754 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Wisconsin (UW) solution
Number of subjects: 81
Study 31331754 — intervention group
Group type: COMPARATOR
Intervention: Histidine-tryptophan-ketoglutarate (HTK) solution
Number of subjects: 81
Study 28441077 — intervention group
Group type: EXPERIMENTAL
Intervention: Conbercept
Number of subjects: 35
Study 28441077 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 35
Study 23731453 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sildenafil (10%) ointment
Number of subjects: 0
Study 23731453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23161898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (75 mg/m2 d1) and pemetrexed (500 mg/m2 d1) q3 weeks
Number of subjects: 132
Study 23161898 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (50 mg/m2 d1 + 8) and vinorelbine (25 mg/m2 d1, 8, 15, 22) q4 weeks
Number of subjects: 132
Study 21795671 — intervention group
Group type: EXPERIMENTAL
Intervention: Lace-up ankle braces
Number of subjects: 1460
Study 21795671 — intervention group
Group type: COMPARATOR
Intervention: Control group (no braces)
Number of subjects: 1460
Study 21795671 — intervention group
Group type: EXPERIMENTAL
Intervention: Lace-up ankle braces (for players with previous ankle injury)
Number of subjects: 1460
Study 21795671 — intervention group
Group type: COMPARATOR
Intervention: Control group (for players with previous ankle injury)
Number of subjects: 1460
Study 21795671 — intervention group
Group type: EXPERIMENTAL
Intervention: Lace-up ankle braces (for players without previous ankle injury)
Number of subjects: 1460
Study 21795671 — intervention group
Group type: COMPARATOR
Intervention: Control group (for players without previous ankle injury)
Number of subjects: 1460
Study 21795671 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1460
Study 19349544 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy
Number of subjects: 3799
Study 16775558 — intervention group
Group type: COMPARATOR
Intervention: Treadmill walking
Number of subjects: 23
Study 16775558 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground walking
Number of subjects: 23
Study 17409841 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.0 mg/m on days 1, 4, 8, and 11 plus docetaxel 75 mg/m on day 1, cycled every 21 days.
Number of subjects: 36
Study 17409841 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus docetaxel
Number of subjects: 36
Study 10468521 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure balloon inflation (15 to 20 atm)
Number of subjects: 934
Study 10468521 — intervention group
Group type: COMPARATOR
Intervention: Low-pressure balloon inflation (8 to 13 atm)
Number of subjects: 934
Study 8935812 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine 10 mg/day (Olz10.0)
Number of subjects: 152
Study 8935812 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine 1 mg/day (Olz1.0)
Number of subjects: 152
Study 8935812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 1743840 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional treatment with a newly designed brace
Number of subjects: 200
Study 1743840 — intervention group
Group type: COMPARATOR
Intervention: Operation
Number of subjects: 200
Study 7181299 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphate (1 mg m‐3)
Number of subjects: 33
Study 7181299 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphate (0.1 mg m‐3)
Number of subjects: 33
Study 7181299 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbachol after sulphate exposure
Number of subjects: 33
Study 7181299 — intervention group
Group type: COMPARATOR
Intervention: NaCl aerosol
Number of subjects: 33
Study 31529447 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracuff pressure of 10 cmH2O
Number of subjects: 72
Study 31529447 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracuff pressure of 30 cmH2O
Number of subjects: 72
Study 31529447 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracuff pressure of 60 cmH2O
Number of subjects: 72
Study 31529447 — intervention group
Group type: COMPARATOR
Intervention: Pre-pneumoperitoneum
Number of subjects: 72
Study 31529447 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-pneumoperitoneum
Number of subjects: 72
Study 30552244 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy-led care
Number of subjects: 60
Study 30552244 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 60
Study 27182042 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 0.9 mg/day
Number of subjects: 257
Study 27182042 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 257
Study 25756492 — intervention group
Group type: EXPERIMENTAL
Intervention: Appearance-based educational video
Number of subjects: 50
Study 25756492 — intervention group
Group type: COMPARATOR
Intervention: Health-based educational video
Number of subjects: 50
Study 23859670 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Group Motivational Interviewing (AGMI)
Number of subjects: 0
Study 23859670 — intervention group
Group type: COMPARATOR
Intervention: Community Service (CS)
Number of subjects: 0
Study 21037100 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8(+) T cells gaining access to lesional epithelium
Number of subjects: 0
Study 21037100 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular endothelial expression of mucosal addressin cell adhesion molecule-1
Number of subjects: 0
Study 21037100 — intervention group
Group type: EXPERIMENTAL
Intervention: T cells isolated from dysplastic mucosa
Number of subjects: 0
Study 21037100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysplastic lesions
Number of subjects: 0
Study 18097503 — intervention group
Group type: EXPERIMENTAL
Intervention: G. lucidum 6 mg
Number of subjects: 50
Study 18097503 — intervention group
Group type: EXPERIMENTAL
Intervention: G. lucidum 0.6 mg
Number of subjects: 50
Study 18097503 — intervention group
Group type: EXPERIMENTAL
Intervention: G. lucidum 60 mg
Number of subjects: 50
Study 18097503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 16855942 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics (group I)
Number of subjects: 129
Study 16855942 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetics (group II)
Number of subjects: 129
Study 12631528 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic inpatients
Number of subjects: 28
Study 12631528 — intervention group
Group type: COMPARATOR
Intervention: Social drinking controls
Number of subjects: 28
Study 16464206 — intervention group
Group type: COMPARATOR
Intervention: Generic instruments
Number of subjects: 0
Study 16464206 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific measures
Number of subjects: 0
Study 16464206 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological measures
Number of subjects: 0
Study 9381994 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 21
Study 9381994 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin
Number of subjects: 21
Study 9381994 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 21
Study 8269452 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (5 or 10 mg once daily for 14 days)
Number of subjects: 96
Study 8269452 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine (15 mg twice daily for 14 days)
Number of subjects: 96
Study 8269452 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (5 or 10 mg once daily)
Number of subjects: 96
Study 8269452 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine (15 mg twice daily)
Number of subjects: 96
Study 8269452 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 96
Study 4041344 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute administration of nisoldipine
Number of subjects: 9
Study 4041344 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued administration of nisoldipine
Number of subjects: 9
Study 4041344 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 9
Study 30509713 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron supplementation (100 mg/d for 8 weeks)
Number of subjects: 80
Study 30509713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 26833798 — intervention group
Group type: COMPARATOR
Intervention: First confidence interval approach using Bonferroni adjustment
Number of subjects: 0
Study 26833798 — intervention group
Group type: COMPARATOR
Intervention: Second confidence interval approach using randomization tests
Number of subjects: 0
Study 26833798 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed approaches using hypergeometric confidence intervals
Number of subjects: 0
Study 24386927 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered behavioral intervention; 1 session per month for 6 months
Number of subjects: 0
Study 24386927 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered behavioral intervention
Number of subjects: 0
Study 22771173 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 91
Study 22771173 — intervention group
Group type: COMPARATOR
Intervention: Waiting (WAIT for delayed MBCT)
Number of subjects: 91
Study 20349155 — intervention group
Group type: EXPERIMENTAL
Intervention: Faith community nurse referral
Number of subjects: 100
Study 20349155 — intervention group
Group type: COMPARATOR
Intervention: Telephone-assisted physician appointment
Number of subjects: 100
Study 18672118 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric Vacuum Aspiration (EVA)
Number of subjects: 0
Study 18672118 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Vacuum Aspiration (MVA)
Number of subjects: 0
Study 18672118 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 15922977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 170
Study 15922977 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 170
Study 12478123 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended node dissection
Number of subjects: 123
Study 12478123 — intervention group
Group type: COMPARATOR
Intervention: Limited node dissection
Number of subjects: 123
Study 12478123 — intervention group
Group type: EXPERIMENTAL
Intervention: Both extended and limited node dissection
Number of subjects: 123
Study 10394177 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram therapy (40 mg i.v. bolus immediately after admission to the ICU)
Number of subjects: 0
Study 10394177 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram therapy (continuous infusion over 24 hours)
Number of subjects: 0
Study 10394177 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10394177 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram therapy
Number of subjects: 0
Study 10394177 — intervention group
Group type: COMPARATOR
Intervention: Control group of out-patients
Number of subjects: 0
Study 8907717 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem administered at 08:00 (AM)
Number of subjects: 23
Study 8907717 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem administered at 22:00 (HS)
Number of subjects: 23
Study 1794358 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified pneumococcal polysaccharide vaccines
Number of subjects: 0
Study 1794358 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of more highly immunogenic vaccines (linked polysaccharides to protein carriers)
Number of subjects: 0
Study 6884024 — intervention group
Group type: EXPERIMENTAL
Intervention: Norinyl
Number of subjects: 0
Study 6884024 — intervention group
Group type: COMPARATOR
Intervention: Brevicon
Number of subjects: 0
Study 31067674 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina maxima with PEP (SE)
Number of subjects: 52
Study 31067674 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with PEP (Ex)
Number of subjects: 52
Study 31067674 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina maxima without PEP (Sm)
Number of subjects: 52
Study 31067674 — intervention group
Group type: COMPARATOR
Intervention: Placebo without PEP (C)
Number of subjects: 52
Study 29128300 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (20-25 kcal/kg per day)
Number of subjects: 2410
Study 29128300 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition (20-25 kcal/kg per day)
Number of subjects: 2410
Study 29128300 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 2410
Study 29128300 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 2410
Study 25925751 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive heat maintenance (PHM) jacket
Number of subjects: 16
Study 25925751 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal attire and performing 3 × 5 CMJ (NMF)
Number of subjects: 16
Study 25925751 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PHM and NMF (COMB)
Number of subjects: 16
Study 25925751 — intervention group
Group type: COMPARATOR
Intervention: Normal-training attire (CON)
Number of subjects: 16
Study 24220099 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month multi-strategy programme delivered via playgroups
Number of subjects: 716
Study 21369791 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5, 10, or 20 mg daily; 35 mg once-weekly; 35 mg twice-weekly; 70 mg once-weekly)
Number of subjects: 17291
Study 21369791 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 17291
Study 21369791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17291
Study 20691641 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin 11.25 mg subcutaneously every 12 weeks
Number of subjects: 204
Study 20691641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 20691641 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin
Number of subjects: 204
Study 19419930 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitargeted therapy
Number of subjects: 0
Study 19419930 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies with traditional chemotherapy and radiation therapy
Number of subjects: 0
Study 19419930 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitargeted inhibitors
Number of subjects: 0
Study 16491252 — intervention group
Group type: EXPERIMENTAL
Intervention: Happydent chewing gum (3.38 mg of fluoride as monofluorophosphate)
Number of subjects: 15
Study 16491252 — intervention group
Group type: COMPARATOR
Intervention: Trident chewing gum (control)
Number of subjects: 15
Study 12568272 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular therapy using magnetic pearls (Group C)
Number of subjects: 120
Study 12568272 — intervention group
Group type: COMPARATOR
Intervention: Auricular therapy using Junci Medulla (Group A)
Number of subjects: 120
Study 12568272 — intervention group
Group type: COMPARATOR
Intervention: Auricular therapy using Semen Vaccariae (Group B)
Number of subjects: 120
Study 10792330 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment with low dose ethinyl oestradiol (0.05 microgram/kg/day)
Number of subjects: 19
Study 10792330 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily (OD) injections of GH (6 IU/m2/day)
Number of subjects: 19
Study 10792330 — intervention group
Group type: COMPARATOR
Intervention: Twice daily (BID) injections of GH (6 IU/m2/day)
Number of subjects: 19
Study 10792330 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-GH treatment with adult dosage of oestrogens
Number of subjects: 19
Study 8814838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical chemotherapy with epirubicin (20 mg/40 mL saline)
Number of subjects: 75
Study 8814838 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 75
Study 1495577 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic therapy using two standard anti-epileptic drugs
Number of subjects: 72121
Study 6519902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclazindol (three different doses)
Number of subjects: 7
Study 6519902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31268180 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin, cisplatin and capecitabine (ECX) chemotherapy with bevacizumab (B)
Number of subjects: 1063
Study 31268180 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin, cisplatin and capecitabine (ECX) chemotherapy without bevacizumab (B)
Number of subjects: 1063
Study 31268180 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall surgical complications
Number of subjects: 1063
Study 31268180 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory complications
Number of subjects: 1063
Study 31268180 — intervention group
Group type: EXPERIMENTAL
Intervention: R1 resection rate
Number of subjects: 1063
Study 31268180 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node harvest
Number of subjects: 1063
Study 29801652 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 min cycling at 40% power at maximal aerobic capacity (Pmax) with 15 min passive recovery (90HT)
Number of subjects: 30
Study 29801652 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 min cycling at 40% Pmax with 15 min CWI recovery (90CWI)
Number of subjects: 30
Study 29801652 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min cycling alternating between 40% and 70% Pmax, with 15 min passive recovery (30HT)
Number of subjects: 30
Study 29801652 — intervention group
Group type: COMPARATOR
Intervention: Baseline (BASE)
Number of subjects: 30
Study 26728766 — intervention group
Group type: EXPERIMENTAL
Intervention: CHoBI7 intervention (handwashing with soap and water treatment for 7 days)
Number of subjects: 401
Study 26728766 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 401
Study 23795621 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodGYM (computerized cognitive behavioural therapy)
Number of subjects: 637
Study 23795621 — intervention group
Group type: COMPARATOR
Intervention: Informational websites (control)
Number of subjects: 637
Study 22687889 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin, amoxicillin and omeprazole (CAO)
Number of subjects: 250
Study 22687889 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin, amoxicillin and omeprazole (LAO)
Number of subjects: 250
Study 20438568 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited shock wave therapy (SWT)
Number of subjects: 36
Study 20438568 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 36
Study 17642523 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA 900 mg monotherapy for 5 days
Number of subjects: 90
Study 17642523 — intervention group
Group type: COMPARATOR
Intervention: DHA 600 mg + mefloquine [MQ] 750 mg combination regimen
Number of subjects: 90
Study 16036192 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 80
Study 11942956 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy (CRN) offered to patients with performance status of 0 or 1.
Number of subjects: 268
Study 11942956 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment for patients with inoperable primary tumors.
Number of subjects: 268
Study 11942956 — intervention group
Group type: COMPARATOR
Intervention: Patients with metastatic disease at presentation.
Number of subjects: 268
Study 11942956 — intervention group
Group type: COMPARATOR
Intervention: Patients with inoperable primary tumors.
Number of subjects: 268
Study 11942956 — intervention group
Group type: COMPARATOR
Intervention: Patients with performance score > or = 2.
Number of subjects: 268
Study 11991547 — intervention group
Group type: COMPARATOR
Intervention: Leukotriene receptor antagonists
Number of subjects: 0
Study 9835454 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐CA
Number of subjects: 20
Study 9835454 — intervention group
Group type: COMPARATOR
Intervention: 99mTc‐SC
Number of subjects: 20
Study 7926288 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients
Number of subjects: 21
Study 7926288 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 21
Study 2780087 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm crank ergometry
Number of subjects: 11
Study 2780087 — intervention group
Group type: COMPARATOR
Intervention: Wheelchair treadmill ergometry
Number of subjects: 11
Study 798708 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 20 mg
Number of subjects: 10
Study 798708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7021260 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 36
Study 7021260 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone‐17‐butyrate (HCB)
Number of subjects: 36
Study 31191105 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel resistance exercise training (ETG; n = 18) for 6 weeks (2 to 3 days per week)
Number of subjects: 36
Study 31191105 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel resistance exercise training (ETG; n = 18)
Number of subjects: 36
Study 31191105 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON; n = 18)
Number of subjects: 36
Study 29023915 — intervention group
Group type: EXPERIMENTAL
Intervention: OCA 10 mg
Number of subjects: 59
Study 29023915 — intervention group
Group type: EXPERIMENTAL
Intervention: OCA 50 mg
Number of subjects: 59
Study 29023915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59